INDEX OF SUBJECTS FOR VOLUME 46

Abelcet
  clinical effectiveness, 185
Acinetobacter spp.
  antibiotic resistance, 436, 448, 726, 742, 751
  bacteraemia, 741
  carbapenem resistance, 451, 730
  clinical importance, 721
  clinical problems, 740
  computer analysis of DNA fingerprinting gels, 314
  epidemiology, 724
  experimental models of infection, 738
  β-lactam resistance and use of inhibitor combinations, 728
  meningitis, 723, 741
  molecular basis of aminoglycoside resistance, 731
  molecular basis of quinolone resistance in *A. baumannii*, 735
  nosocomial infections, 436, 448, 721
  respiratory tract infections, 723, 738, 740
  species identification and typing, 724
  treatment options, 730, 742
  virulence, 738
Actinobacillus actinomycetemcomitans
  susceptibility of biofilms to oral antiseptics, 425
Adherence
  coliforms to caecal epithelium, 571
  of enteropathogenic *E. coli*, 67
  H. pylori in cell cultures, 117, 825
  of *S. marcescens*, 905
  staphylococci to prosthetic devices, 75, 285
Aeromonas spp.
  A. hydrophila, plasmids, 833
  resistance to carbapenems, 451
  siderophore production in *A. hydrophila*, 833
AIDS patients
  detection of JC virus in CSF, 256
  monitoring of antiviral therapy, 256
  new herpesvirus and, 433
  zoonoses and cross-protective immunity, 9
AmBisome
  clinical effectiveness, 185
Amino acids
  utilisation by *H. pylori*, 793
Aminoglycoside resistance
  in *Acinetobacter* spp., 731
  of *S. marcescens*, 905
Amniotic fluid
  PCR detection of *T. gondii*, 92
Amoxycillin
  resistance of gram-negative nosocomial isolates, 437
  resistance of respiratory tract isolates, 443
Amphocil
  clinical effectiveness, 185
Amphotericin B
  lipid compexes, 185
  therapeutic considerations, 185
Amplification technology
  possibilities and limitations, 188
Anaerobes
  in chronic maxillary sinusitis, 430
  mucosa-associated bacterial flora, 85
  see also Specific genera
Animals *see* Cats, Gerbil model, Mouse model, Rabbit model, Rat model, Zoonoses
Anthrax, 267
Anthroponosis
  H. pylori in cats, 372
Antibiotic resistance, 436
  Acinetobacter spp., 436, 448, 726, 742, 751
  bacteraemia and, 445
  Bacteroides spp., and β-lactams, 985
  carbapenems, 451
  detection by amplification-based technology, 190
  epidemiology of, 442
  fluoroquinolones, mechanisms and epidemiology, 457
  of *H. influenzae*, 442
  infection in intensive care units, 447
  inhibitor-resistant and extended-spectrum TEM and SHV β-lactamases, 454
  of *M. catarrhalis*, 364, 443
  M. tuberculosis, solutions to problems, 531
  meningitis and, 445, 902
  methicillin-resistant *S. aureus*, 145, 214, 297, 439, 446, 448, 773
  multidrug-resistant enterococci, 150
  multidrug-resistant tuberculosis, 847
  multiresistant *K. pneumoniae*, 921
  nosocomial gram-negative, 436
  nosocomial gram-positive, 439
  outer membranes of gram-negative bacilli, 1
  overcoming problems, 464
  quinolones, and *N. gonorrhoeae*, 383
  quinolones, and *Salmonella* serotype Typhimurium, 623
  resistotyping of campylobacters, 34
  respiratory tract infections, 442
  of *S. marcescens*, 905
  S. pneumoniae, 444, 445
  source of, 461
  vancomycin, and enterococci, 150, 442, 448, 449
  vancomycin, and staphylococci, 451
  zoonotic infections and, 26
Antibiotics and other antimicrobial substances
  antibacterial peptides and gram-negative bacilli, 1
  arbekacin-loaded implants in osteomyelitis, 779
  breakthrough infection during therapy, 517
  cefsulodin in selective medium for *H. influenzae*, 883
  cytarabine in JC virus infection, 256
  epidemiological typing of CNS, 195
  in food animals, and zoonoses, 26
  lipid compexes of amphotericin B, 185
  in management of meningitis, 901
  susceptibility of *A. actinomycetemcomitans* biofilms to oral antiseptics, 425
  susceptibility of *M. catarrhalis*, 364
  susceptibility of *S. marcescens*, 905
  treatment of brucellosis, 102
  treatment of tuberculosis, 531
  usage, and development of resistance, 462
  see also Specific agents
Antibodies
  autoantibodies, 669
  Borrelia duttonii, 675
  C. pneumoniae, 537
  cardiolipin, 965
  H. pylori, 657
  in hydatid disease, 859
  lysozyme, 669
  M. catarrhalis, 367
  T. pallidum, 965
  see also Monoclonal antibodies
Antigens
  of *Borrelia* spp., 268
  of *Brucella* spp., 101, 267, 801
  of *C. albicans*, 747
  C. pneumoniae, contaminated with mycoplasma, 419
  in controlled release vaccines, 975
  cytomegalovirus, 717
  E. coli: cytokine response, 139
  of *F. tularensis*, 268
  foreign, carried by salmonellae, 129
  of *H. pylori*, 819
  in hydatid disease, 859
  of influenza virus, 813
  M. catarrhalis, 366
  of new herpesvirus, 433
  of *P. falciparum*, 357

protective, of *B. anthracis*, 267
of *T. gondii*, 587
of *V. cholerae*, 1011
of *Y. pestis*, 268
Antiseptics, oral, 425
Antiserum
against *S. marcescens*, 251
Arbekacin
treatment of *S. aureus* osteomyelitis, 779
Arthritis
S. aureus-induced, 208
Arylamidase
dipeptidyl, of *B. splanchnicus*, 547
Asparagine
utilisation by *H. pylori*, 793
Aspergillus spp.
response to lipid compexes of amphotericin B, 185
Atherosclerosis, 535
Autoantibodies
lysozyme, 669
Auxotyping
E. dermatitidis, 757
N. gonorrhoeae, 383

Bacilli, gram-negative
antibacterial peptides and, 1
Bacillus spp.
B. cereus, resistance to carbapenems, 451
vaccines against *B. anthracis*, 267
Bacteraemia
Acinetobacter spp., 741
antibiotic resistance and, 445
breakthrough infection during therapy, 517
E. coli, 446, 506
S. aureus, 446
Bacteriophages *see* Phage typing
Bacteroides spp.
B. fragilis, resistance to carbapenems, 451
B. splanchnicus, dipeptidyl arylamidase, 547
β-lactam resistance, 807, 985
metallo-β-lactamases of *B. fragilis*, 807
mucosa-associated bacterial flora, 85
treatment of infections, 985
BCG vaccine, 9
Biofilms
A. actinomycetemcomitans, 425
Blood
epidemiology of antibiotic resistance, 445
invasion by *P. mirabilis*, 407
PCR detection of *M. tuberculosis* DNA, 495
surveillance cultures, 785
Bone marrow transplant patients, 785
BOOK REVIEWS
A Guide to Specimen Management in Clinical Microbiology (J. M. Miller), 715
Adeno-Associated Virus (AAV) Vectors in Gene Therapy: Current Topics in Microbiology and Immunology 218 (edited by K. I. Berns and C. Giraud), 893
Antimicrobial Chemotherapy, 3rd edition (edited by D. Greenwood), 98
ASM Pocket Guide to Clinical Microbiology (P. R Murray), 528
Bacterial Invasiveness: CTMI 209 – Current Topics in Microbiology and Immunology (edited by V. L. Miller), 184
Bacterial Protein Toxins (edited by P. L. Frandsen, J. E. Alouf, P. Falmagne *et al.*), 182
Cap-Independent Translation (edited by P. Sarnow), 99
Case Presentations in Clinical Infections (I. K. Hosein and M. B. Llewelyn), 894
Cholera and the Ecology of *Vibrio cholerae* (edited by B. S. Drasar and B. D. Forrest), 811
Clostridial Neurotoxins (edited by C. Montecucco), 97
Developments in Biological Standardization, volume 85: Genetics of Streptococci, Enterococci and Lactococci (edited by J. J. Ferretti, M. S. Gilmore, T. R. Klaenhammer and F. Brown), 100
Environmental Microbiology: A Laboratory Manual (I. L. Pepper, C. P. Gerba and J. W. Brendecke), 99
Hospital Infection Control: Policies and Practical Procedures (J. Philpott-Howard and M. Casewell), 529
Invasive Fungal Infections in Cancer Patients, volume 2/number 1: Bailliere's Clinical Infectious Diseases (edited by F. Meunier), 98
Lecture Notes on Infectious Diseases, 5th edition (B. K. Mandal, E. G. L. Wilkins, E. M. Dunbar and R. T. Mayon-White), 100
Medical Microbiology: A Short Course (E. J. Baron, R. S. Chang, D. H. Howard, J. N. Miller and J. A. Turner), 184
Methods in Molecular Genetics, volume 7: Viral Gene Techniques (edited by K. W. Adolph), 528
Microbial Physiology, 3rd edition (A. G. Moat and J. W. Foster), 97
Microbiology and Infection: A clinically-orientated core text with self-assessment (T. J. J. Inglis), 182
Pathology of Septic Shock: Current Topics in Microbiology and Immunology, volume 216 (edited by E. T. Rietschel and H. Wagner), 811
Principles and Practice of Clinical Mycology (edited by C. C. Kibbler, D. W. R. Mackenzie and F. C. Odds), 183
Problem-Orientated Clinical Microbiology and Infection (H. Humphreys and W. L. Irving), 528
Slide Atlas of Fungal Infection – The Set (M. D. Richardson, D. W. Warnock and C. K. Campbell), 812
The Infectious Diseases Manual (D. Wilks, M. Farrington and D. Rubenstein), 183
The Molecular Repertoire of Adenoviruses I: Virion Structure and Infection (edited by W. Doerfler and P. Bohm), 97
The Molecular Repertoire of Adenoviruses II: Molecular Biology of Virus-Cell Interactions (edited by W. Doerfler and P. Bohm), 97
The Molecular Repertoire of Adenoviruses III: Biology and Pathogenesis (edited by W. Doerfler and P. Bohm), 97
Therapeutic Guidelines in Paediatric Infections (S. Nadel, R. Heyderman and N. Klein), 182
Toward Anti-Adhesion Therapy for Microbial Diseases: Advances in Experimental Medicine and Biology, volume 408 (edited by I. Kahane and I. Ofek), 893
Toxoplasma gondii (edited by U. Gross), 811
Tuberculosis: Current Topics in Microbiology and Immunology 215 (edited by T. M. Shinnick), 894
Bordetella pertussis
current status of acellular vaccines, 817
Borrelia spp.
antigens, 268
B. duttonii, protective activity of immunoglobulins, 675
vaccines, 268
Brucella spp.
antigenic structure, 101
antigens, 268
diagnosis of disease, 102
mechanisms of pathogenicity, 102
molecular genetics, 101
T-cell antigens, 801
treatment and prevention of disease, 102
vaccines, 267
Brucellergene, 801
Brucellosis
recent advances in, 101
Buffalopox virus, 19
Burkholderia pseudomallei
ribotyping, 565
toxin production, 557
Buruli ulcer, 9

E-Cadherin, 681
Calymmatobacterium granulomatis
growth and cultural characteristics, 579
Campylobacters
C. jejuni, PFGE analysis, 157
food- and milk-borne zoonotic infections, 11
resistotyping of *C. coli*, 34
resistotyping of *C. jejuni*, 34
Cancer patients
breakthrough infection during therapy, 517
Candida spp.
C. albicans antigens, 747
C. albicans, interaction with neutrophils, 747
C. albicans, satellite colonies, 326
C. albicans, structured aerial mycelia, 326

electron microscopy of phenotypically switched *C. albicans*, 326
response to lipid compexes of amphotericin B, 185
Candle jars, 354
Carbapenems
resistance of *Acinetobacter* spp., 451, 730
resistance mechanisms, 451
Cardiolipin antibodies, 965
Cardiotropic viruses, 536
Castleman's disease, 433
Catheter-associated infection, 517
Cats
helicobacter infections in, 372
Cefsulodin chocolate blood agar, 883
Cefuroxime
resistance of gram-negative nosocomial isolates, 437
resistance of respiratory tract isolates, 443
Cell culture
adherence of *H. pylori*, 117, 825
C. difficile toxin A binding to epithelial cells, 953
cytokine response to *E. coli*, 139
LYM-1, and vacuolating toxin of *H. pylori*, 705
proliferation-dependent entry of *L. monocytogenes*, 681
R. rickettsii in tick cell lines, 839
toxicity of *C. sporogenes* haemorrhagic toxin, 270
Cephalosporins
resistance, in ICUs, 448
Cerebrospinal fluid
adherence of staphylococci to prostheses, 75, 285
detection of JC virus, 256
epidemiology of antibiotic resistance, 445
Cervical neoplasia, 54
Chlamydia
C. pneumoniae, in coronary heart disease, 537
comparison of *C. trachomatis* EIA kits, 711
diagnosis of *C. pneumoniae* infection, 959
mycoplasma contamination in *C. pneumoniae* antigens, 419
surface projections of *C. trachomatis*, 1017
Chloramphenicol
in management of meningitis, 901
Ciprofloxacin
epidemiology of resistance, 457
resistance of *E. coli*, 446
resistance of gram-negative nosocomial isolates, 437
resistance of *K. pneumoniae*, 446
resistance of respiratory tract isolates, 443
Clostridia
C. difficile toxin A, 953
effect of lactulose on *C. difficile*, 80
haemorrhagic toxin of *C. sporogenes*, 270
Co-amoxiclav
resistance of gram-negative nosocomial isolates, 437
resistance of respiratory tract isolates, 443
Coagulase
production by *S. aureus*, 222
Coliform bacteria
selective translocation, 571
Colon
mucosa-associated bacterial flora, 85
Computer programs
DNA fingerprint analysis, 314
Concanavalin-A
in response to *S. marcescens* infection, 251
Coronary heart disease
and infection, 535
Cowpox, 18
Coxsackie B viruses, 536
Cryptococcus spp.
response to lipid compexes of amphotericin B, 185
Cryptosporidiosis, 21
Culturability/viability of bacteria, 629
Culture media
for detection of *P. alcalifaciens*, 524
Kirchner's, recovery of *M. tuberculosis*, 260
for oral spirochaetes, 106
for recognition and identification of *Proteeae*, 39
for recovery of *H. influenzae*, 883
Cystic fibrosis, 471, 757, 883
Cytarabine
in JC virus infection 256,
Cytokines
GM-CSF-modulated phagocytosis of *T. beigelii*, 321
interleukin-8, and *P. aeruginosa*, 471
in mucosal IgA response to *Salmonella* serotype Dublin, 1037
role in experimental listeriosis, 239
secretion in *E. coli* pyelonephritis, 139
Cytomegalovirus
antigens, 717
in coronary heart disease, 536
diagnosis of infection and disease, 717
monoclonal antibodies, 717
Cytotoxins
C. sporogenes haemorrhagic toxin, 270
of *H. pylori*, 705
putative *M. ulcerans* toxin, 333

Dexamethasone
in management of meningitis, 901
Diarrhoea
media for detection of *P. alcalifaciens*, 524
surface properties of enteropathogenic *E. coli*, 67
DNA
16S rDNA associated with Whipple's disease, 340
analysis of leptospiral serovars by RAPD fingerprinting, 927
computer programs for fingerprint analysis, 314
detection of cytomegalovirus, 718
detection of *Vibrio* toxin genes, 398
fingerprinting of *E. coli* bacteraemia isolates, 506
genetic differentiation of *M. tuberculosis* isolates, 501
genome organisation of *S. aureus*, 297
PCR detection of *M. tuberculosis* in blood, 495
PCR detection of *P. carinii*, 665
PCR-based differentiation of *Leptospira*, 173
PFGE profiles of *C. jejuni*, 157
possibilities and limitations of ampification technology, 188
RAPD analysis of *Acinetobacter* spp., 314
RAPD analysis of *E. dermatitidis*, 757
RAPD typing of *S. aureus*, 222
RFLP analysis of *S. aureus*, 297
RFLP typing of *M. avium*, 933
specific for clonal population of *S. aureus*, 997
typing methods for *H. influenzae*, 763
typing methods for *M. catarrhalis*, 366
Donovanosis, 579
Dormancy, 629

Echinococcus granulosus
serological evaluation of disease, 859
Echinococcus spp.
zoonotic infections, 24
EIA
comparison of kits for *C. trachomatis*, 711
Electron microscopy
C. albicans colonies, 326
characterisation of spirochaetes, 110
scanning, 326
surface projections of *C. trachomatis*, 1017
Electrophoresis
counter-current immuno-electrophoresis, 1041
enzyme, 1027
multilocus enzyme, 204
pulsed-field gel, 150, 157, 383, 501, 506
ELISA
diagnosis of *C. pneumoniae* infection, 959
Encephalitis
T. gondii, 597
Endoscopy
of maxillary sinus, 430
Enterobacter spp.
antibiotic resistance and noscomial infections, 436
fluoroquinolone resistance, 458
resistance to carbapenems, 451
Enterococci
antibiotic resistance, 150, 442, 447
in intensive therapy units, 447
multi-drug-resistant, 150
nosocomial infections, 442, 447
plasmid typing, 150
vancomycin-dependent, 451

vancomycin-resistant, 150, 442, 448, 449
Enterotoxins
production by *S. aureus*, 214
of *V. cholerae*, 398
of *V. mimicus*, 398
Enzyme electrophoresis *see* Electrophoresis
Epidemiology
Acinetobacter spp., 724
of antibiotic resistance: blood and CSF, 445
of antibiotic resistance: intensive care units, 447
of antibiotic resistance: respiratory tract infections, 442
characterisation of *H. influenzae*, 204
coagulase-negative staphylococci, 195
coronary heart disease and infection, 535
epidemic isolates of *Salmonella* Enteritidis, 377
fluoroquinolone resistance, 457
of *M. tuberculosis*, 501
multiresistant *K. pneumoniae*, 921
ribotyping of *Salmonella* serotype Typhimurium, 307
of *S. marcescens*, 905, 1027
V. cholerae O1 isolates, 611
vancomycin-resistant enterococci, 449
Epstein-Barr virus, 536
Erythromycin
resistance of respiratory tract isolates, 443
Escherichia coli
antibiotic resistance, 28, 436, 446, 456, 458
antibiotic-exposed, 122
bacteraemia, 446, 506
cytokine response to antigens, 139
enteropathogenic (EPEC), 67
EPEC adherence factor plasmid, 67
fluoroquinolone resistance, 458
food-borne infections, 13
hydrophobicity, 67
β-lactamases, 456
monoclonal antibodies, 122
nosocomial infections, 436
role of type-1 fimbriae in UTI, 403
surface properties of diarrhoeagenic isolates, 67
verocytotoxic, 13
zoonoses, 13, 28
Ethambutol
in treatment of tuberculosis, 531
Exophiala dermatitidis
in cystic fibrosis, 757
fatty acid methyl ester profiles, 757
phenotypic and genotypic fingerprinting, 757

Faeces
effect of lactulose on flora, 80
media for detection of *P. alcalifaciens*, 524
Fatty acid
effect of lactulose on faecal flora, 80
methyl ester profiles, of *E. dermatitidis*, 757
modifying enzyme, of *S. epidermidis*, 693
Fimbriae
type-1, in pathogenesis of UTI, 403
Flagellin
of *Salmonella*, 129
Flaviviruses
Murray Valley encephalitis epitope expressed in *Salmonella*, 129
zoonoses, 8
Flow cytometry, 825
Fluid restriction
in management of meningitis, 902
Fluorescence
micro-immunofluorescence assay for *C. pneumoniae*, 959
treponemal antibody absorption test, 965
Fluoroquinolones
mechanisms and epidemiology of resistance, 457
resistance of *S. marcescens*, 458, 906
susceptibility of *N. gonorrhoeae*, 383
Food-borne infections
campylobacters, 11
E. coli, 13
enterotoxin production by *S. aureus*, 214
epidemic isolates of *Salmonella* Enteritidis, 377
salmonellosis, 12
zoonotic, 11
Francisella tularensis
vaccine, 268
Fungaemia
breakthrough infection during therapy, 517
Fusobacterium spp.
F. necrophorum, classification by pathogenic effects in mice, 879
F. necrophorum, lipopolysaccharides, 873
F. necrophorum, phenotypic characteristics, 865, 873
F. necrophorum, taxonomy, 865
F. nucleatum, in chronic maxillary sinusitis, 430

Gastritis
animal models of *H. pylori* infection, 391, 657
Genes
16S rRNA, associated with Whipple's disease, 340
differentiation of *M. tuberculosis* isolates, 501
discrimination of *Salmonella* serotype Eimsbuettel, 617
fingerprinting of *E. coli* bacteraemia isolates, 506
genome organisation of *S. aureus*, 297
linkage between *ure* and *trh* in *V. parahaemolyticus*, 639
molecular genetics of *Brucella* spp., 101
PCR detection of *Vibrio* toxin genes, 398
population genetics of *M. catarrhalis*, 366
probes for oral treponemes, 110
RAPD analysis of *E. dermatitidis*, 757
S. agalactiae β gene and gene product variations, 1005
Gentamicin
resistance of gram-negative nosocomial isolates, 437
Gerbil model
H. pylori infection, 391
Giardia spp.
zoonotic infections, 23
Glutamine
utilisation by *H. pylori*, 793
GM-CSF
modulation of phagocytosis of *T. beigelii*, 321
Granuloma inguinale, 579
Growth promoters
use in food animals, 26

Haemagglutinating activity
of *H. pylori*, 117
Haemagglutinin
of influenza virus, 813
Haemolytic activity
gene in *V. parahaemolyticus*, 639
of *M. tuberculosis*, 233
of *P. aeruginosa*, 471
S. aureus α-haemolysin, 208
Haemophilus influenzae
antibiotic resistance, 442, 454, 458, 901
characterisation by pyrolysis mass spectrometry, 204
epidemiology of antibiotic resistance, 442
fluoroquinolone resistance, 458
β-lactamases, 442, 454, 901
meningitis, 901
population genetic analysis, 204
ribotyping, 763
selective medium, 883
Haemorrhagic toxin
of *C. sporogenes*, 270
Hantavirus infections
zoonotic, 13
Helicobacter pylori
adherence to cell cultures, 117, 825
antibiotic resistance, 442
in coronary heart disease, 537
gerbil model of infection, 391
growth in candle jars, 354
haemagglutinating activity, 117
heat-shock protein, 60, 819, 825
heparan sulphate binding surface proteins, 541
infections in cats, 372
monoclonal antibodies, 60, 819, 825
pathogenicity of spiral and coccoid forms, 657
utilisation of amino acids, 793
vacuolating toxin, 117, 705

Heparan sulphate
binding by *H. pylori*, 541
Herpes simplex virus, 536
Herpesviruses
in coronary heart disease, 536
human herpesvirus-8, 433, 536
sarcoma-associated, 433
Human papillomaviruses
cervical neoplasia and, 54
Hybridisation of DNA
subtractive, 997
Hydatid disease
serology after chemotherapy and surgery, 859
zoonotic, 24
Hydrophobicity
of enteropathogenic *E. coli*, 67
of *S. marcescens*, 906
Hydroxyapatite blocks, antibiotic-loaded, 779

Imipenem
resistance mechanisms, 451
Immune response
mice to *Borrelia duttonii*, 675
mice to influenza A vaccines, 61
to *M. catarrhalis*, 367
to Murray Valley encephalitis epitope expressed in *Salmonella*, 129
to *S. marcescens*, 251
to *T. pallidum*, 669
Immunisation
against *B. pertussis*, 817
against *P. falciparum*, 357
mice against antibiotic-exposed *E. coli*, 122
Immunity
cross-protective, and zoonoses, 6
Immunoassay
identification of oral spirochaetes, 110
Immunofluorescence assay, 959
Immunoglobulins
against *Borrelia duttonii*, 675
mucosal IgA response to *Salmonella* serotype Dublin, 1037
Immunosuppressed patients, 185, 434, 699, 785
Influenza virus
antigens, 813
immune response to influenza A vaccines, 61
pandemics, 813
vaccines, 61, 813
Intensive care units
Acinetobacter spp. infections, 740
antibiotic resistance and, 447
Interferon
response to *E. coli* antigens, 139
response to influenza A vaccines, 61
Interleukin-2
response to *E. coli* antigens, 139
response to influenza A vaccines, 61
Interleukin-5
in mucosal IgA response to *Salmonella* serotype Dublin, 1037
Interleukin-8
response to *P. aeruginosa*, 471
Iron
influence on siderophore production, 833
Isoniazid
in treatment of tuberculosis, 531, 847

JC virus
detection in CSF, 256
Jennerian principle of cross-protective immunity, 6

Kaposi's sarcoma, 433
Kawasaki disease, 536
Klebsiella spp.
antibiotic resistance, 436, 446, 456
epidemiology of multiresistant *K. pneumoniae*, 921
fluoroquinolone resistance, 458
K. pneumoniae, antibiotic resistance, 446
β-lactamases, 454
nosocomial infections, 436

β-Lactamases
of *Acinetobacter* spp., 728
Bacteroides spp., 807, 985
E. coli, 456
of *H. influenzae*, 442, 454, 901
induction and derepressed mutants, 448
inhibitor-resistant and extended-spectrum TEM and SHV, 454
Klebsiella spp., 454
of *M. catarrhalis*, 364, 443
metallo-β-lactamases of *B. fragilis*, 807
of *N. gonorrhoeae*, 383
resistance to carbapenems, 451
of *S. marcescens*, 905
Lactulose
effect on faecal flora, 80
Legionella spp.
L. pneumophila, virulence in suckling mice, 647
resistance to carbapenems, 451
Leprosy 9,, 170
Leptospira spp.
analysis of serovars by RAPD fingerprinting, 927
PCR-based differentiation, 173
vaccines, 268
Leucoencephalopathy, progressive multifocal, 256
Leucotoxins
of *P. haemolytica*, 276
of *S. aureus*, 486
Lipopolysaccharide (LPS)
of *F. necrophorum*, 873
of *S. marcescens*, 907
Listeria monocytogenes
proliferation-dependent cell entry pathways, 681
role of cytokines in infection, 239
Lymph node biopsy specimens, 260
Lysozyme
in immune immobilisation of *T. pallidum*, 669

Macrophages
pathogenesis of type-1 fimbriae, 403
phagocytosis of *S. marcescens*, 251
Malaria
vaccines against, 357
Marek's disease virus, 536
Media *see* Culture media
Melioidosis, 557
Meningitis
Acinetobacter spp., 723, 741
antibiotic resistance and, 445, 902
childhood, management of, 901
H. influenzae, 901
N. meningitidis, 901
S. pneumoniae, 901
Methicillin
discrimination of resistant *S. aureus*, 145
resistance of *S. aureus*, 214, 297, 439, 446, 448, 773
Micro-immunofluorescence assay, 959
Milk-borne zoonotic infections, 11
Monoclonal antibodies
against cytomegalovirus, 717
against *E. coli*, 122
against *H. pylori* heat-shock protein, 60, 819, 825
against oral spirochaetes, 112
against *P. multocida*, 603
against tumour necrosis factor-α, 239
neutrophil-depleting, 239
Monocytes
interleukin-8 response to *P. aeruginosa*, 471
Moraxella (Branhamella) catarrhalis
antibiotic susceptibility, 364
antigens, 366
clinical significance, 362
epidemiology of antibiotic resistance, 443
fluoroquinolone resistance, 458
β-lactamases, 364, 443
nomenclature, 360
nosocomial infection, 363
pathogenicity and virulence, 366
population genetics, 366
typing methods, 366

Morganella spp.
M. morganii, fluoroquinolone resistance, 458
recognition and identification, 39
Mouse model
H. pylori gastritis, 657
immune response to *Borrelia duttonii*, 675
infection by *Acinetobacter* spp., 738
pathogenicity of *F. necrophorum*, 879
protection against *S. marcescens* infection, 251
recrudescence of *T. gondii* infection, 263
role of cytokines in listeriosis, 239
S. aureus arthritis, 208
suckling mice, 647
vaccination against influenza A virus, 61
virulence of *L. pneumophila*, 647
Mucosa-associated bacterial flora, 85
Mucosal IgA response to *Salmonella* serotype Dublin, 1037
Murray Valley encephalitis virus
epitope expressed in *Salmonella*, 129
Mycobacteria
contact-dependent haemolysin of *M. tuberculosis*, 233
cross-protective immunity, 9
detection of *M. leprae* by PCR, 170
detection of *M. tuberculosis*, 164, 495
drug resistance patterns in *M. tuberculosis*, 847
genetic differentiation of *M. tuberculosis* isolates, 501
M. leprae, cross-protective immunity, 9
M. tuberculosis, solutions to drug resistance problems, 531
M. ulcerans, cross-protective immunity, 9
M. ulcerans, putative toxin, 333
M. ulcerans, serological assay, 333
in nucleic acid amplification technology, 188
recovery of *M. tuberculosis* from biopsy specimens, 260
RFLP typing of *M. avium*, 933
in zoonoses, 9
Mycoplasma
contamination in *C. pneumoniae* antigens, 419
pyrolysis mass spectrometry of *M. fermentans*, 348

Nalidixic acid
resistance of *Salmonella* serotype Typhimurium, 623
Neisseria spp.
N. gonorrhoeae, β-lactamase, 383
N. gonorrhoeae, plasmids, 383
N. gonorrhoeae, susceptibility to quinolones, 383
N. gonorrhoeae, typing, 383
N. meningitidis, management of meningitis, 901
Neuraminidase
of influenza virus, 813
Neutrophils
GM-CSF-modulated phagocytosis of *T. beigelii*, 321
interaction with *C. albicans* antigens, 747
role in experimental listeriosis, 239
Nomenclature
M. catarrhalis, 360
proposed new taxa, 633
viable but non-culturable/dormant bacteria, 629
Nosocomial infections
Acinetobacter spp., 436, 448, 721
antibiotic resistance and ITUs, 447
coagulase-negative staphylococci, 195+2
development of resistance, 462
gram-negative, and antibiotic resistance, 436
gram-positive, and antibiotic resistance, 439
M. catarrhalis, 363
S. marcescens, 903, 1027

Oral flora
isolation and identification of spirochaetes, 104
susceptibility of *A. actinomycetemcomitans* to oral antiseptics, 425
Orthopoxvirus
infections, zoonotic, 18
Osteomyelitis
antibiotic-loaded implants, 779
Outer membranes
permeability in gram-negative bacilli, 1

Parapoxvirus infections
zoonotic, 17
Pasteurella spp.
P. haemolytica, characterisation of leucotoxin, 276
P. multocida, identification of serotype D strains, 603
P. multocida, monoclonal antibodies, 603
PCR *see* Polymerase chain reaction
Penicillin
in management of meningitis, 901
resistance of *S. aureus*, 445
resistance of *S. pneumoniae*, 444
Peptides, antibacterial, 1
Peptostreptococcus spp.
in chronic maxillary sinusitis, 430
Periodontal disease
isolation and identification of spirochaetes, 104
susceptibility of *A. actinomycetemcomitans* to oral antiseptics, 425
Phaeohyphomycotic soft tissue disease, 699
Phage typing
epidemic isolates of *Salmonella* Enteritidis, 377
epidemiology of CNS, 195
quality control, 511
of *S. aureus*, 222, 511
Phagocytosis
C. albicans by neutrophils, 747
S. marcescens by macrophages, 251
T. beigelii by neutrophils, 321
Phospholipase C
of *P. aeruginosa*, 471
Pigmentation
of *S. marcescens*, 904
Plague
vaccines against, 268
Plasmids
of *A. hydrophila*, 833
analysis of *N. gonorrhoeae*, 383
EPEC adherence factor, 67
epidemiological typing of CNS, 195
multidrug-resistant enterococci, 150
as source of antibiotic resistance, 462
Plasmodium falciparum
antigens, 357
vaccines, 357
Pleurophomopsis lignicola
soft tissue infection, 699
Pneumocystis carinii
detection of DNA by PCR, 665
Pneumocystosis, 665
Pneumonia
Acinetobacter spp., 723, 738, 740
Polymerase chain reaction
16S rDNA associated with Whipple's disease, 340
arbitrarily primed, 173
contamination of chlamydial antigens with mycoplasma, 419
detection of cytomegalovirus, 717
detection of *M. tuberculosis*, 164, 495
detection of *P. carinii* DNA, 665
detection of *T. gondii*, 92
detection of *U. urealyticum* in urine, 413
detection of *Vibrio* toxin genes, 398
diagnosis of leprosy, 170
differentiation of *Leptospira* spp., 173
fingerprinting *V. cholerae* O1 isolates, 941
identification of *T. mentagrophytes* dermatophytes, 1045
low-stringency, 173
monitoring of antiviral therapy, 256
multiplex, for detection of MRSA, 773
plus ribotyping, of epidemic isolates of *Salmonella* Enteritidis, 377
plus ribotyping, of *H. influenzae*, 763
possibilities and limitations of technology, 188
RAPD-PCR typing of *S. marcescens*, 905, 913
rapid identification of CNS, 45
restriction endonuclease analysis, 173
screening for human papillomavirus infection, 54
Poxviruses, zoonotic, 8, 17
Prevotella spp.
in chronic maxillary sinusitis, 430
PROCEEDINGS OF THE 175TH MEETING OF THE PATHOLOGICAL SOCIETY OF GREAT BRITAIN AND IRELAND, 1057
Prodigiosin
of *S. marcescens*, 904

Prostheses
adherence of staphylococci, 75, 285
breakthrough infection during therapy, 517
Proteeae
recognition and identification, 39
Proteins
antibacterial peptides, 1
heat-shock, of *H. pylori*, 819, 825
heparan sulphate binding, of *H. pylori*, 541
profiles, characterisation of *H. influenzae*, 204
S. aureus protein A, 208, 222
surface adhesins of *S. aureus*, 75
T-cell antigens of *Brucella* spp., 801
temperature-inducible, in *R. rickettsii*, 839
Proteus spp.
ability of *P. mirabilis* to invade blood, 407
fluoroquinolone resistance, 458
proticine production/sensitivity of *P. mirabilis*, 407
recognition and identification, 39
Proticine
production/sensitivity of *P. mirabilis*, 407
Protozoa
zoonotic infections, 20
Providencia spp.
P. alcalifaciens, media for detection and recognition, 524
recognition and identification, 39
Pseudomonas spp.
antibiotic resistance and noscomial infections, 436
P. aeruginosa, fluoroquinolone resistance, 458
P. aeruginosa, haemolytic activity, 471
P. aeruginosa, phospholipase C, 471
resistance to carbapenems, 451
Pyelonephritis
E. coli, 139, 403
Pyrazinamide
in treatment of tuberculosis, 531
Pyrolysis mass spectrometry
characterisation of *H. influenzae*, 204
of *M. fermentans*, 348
taxonomy of *F. necrophorum*, 865

Q fever, vaccine, 268
Quality control
phage typing of *S. aureus*, 511
Quinolones
in management of meningitis, 901
mechanisms and epidemiology of resistance, 457
resistance in *A. baumannii*, 735
resistance, in ITUs, 448
resistance of *Salmonella* serotype Typhimurium, 623
susceptibility of *N. gonorrhoeae*, 383

Rabbit model
pathogenicity of *S. aureus* leucotoxins, 486
S. aureus orthopaedic device-related infection, 75
toxicity of *C. sporogenes* haemorrhagic toxin, 270
Rat model
pneumocystosis, 665
translocation of coliform bacteria, 571
treatment of osteomyelitis, 779
Relapsing fever, 267
Respiratory tract infection
Acinetobacter spp., 723, 738, 740
antibiotic resistance and, 442
C. pneumoniae, 959
chronic obstructive pulmonary disease, 959
Restriction endonuclease analysis, 173
H. influenzae, 763
RFLP typing of *M. avium*, 933
Shigella spp. clinical isolates, 949
Restriction fragment length polymorphisms
analysis of *S. aureus*, 297
typing of *M. avium*, 933
Ribotyping
B. pseudomallei, 565
characterisation of *H. influenzae*, 204
coagulase-negative staphylococci 45,, 195
epidemic isolates of *Salmonella* Enteritidis, 377
H. influenzae, 763
PCR-ribotyping, 377, 763
Salmonella serotype Typhimurium, 307
V. cholerae O1 isolates, 941
Rickettsia spp.
temperature-inducible proteins of *R. rickettsii*, 839
vaccines, 268
Rifampicin
treatment of tuberculosis, 531
RNA
possibilities and limitations of ampification technology, 188

Salmonellae
antibiotic resistance, and zoonoses, 27
epidemiology of *Salmonella* serotype Typhimurium, 307
interleukin-5 and mucosal IgA response, 1037
mechanism of quinolone resistance, 623
Murray Valley encephalitis epitope expressed in flagellin, 129
PCR-ribotyping of epidemic isolates, 377
phenotypic and genotypic discrimination, 617
ribotyping of *Salmonella* serotype Typhimurium, 307
serodiagnosis of typhoid fever, 1041
serotype Dublin, 1037
serotype Eimsbuettel, 617
serotype Enteritidis, 12, 377
serotype Typhimurium, 12, 27, 307, 623
zoonotic salmonellosis, 12
Sarcoma-associated herpes virus, 433
SDS-PAGE
epidemiological typing of CNS, 195
taxonomy of *F. necrophorum*, 865
Seoul virus, 13
Serology
diagnosis of typhoid fever, 1041
diagnosis of ulcerans disease, 333
evaluation of hydatid disease, 859
Serotyping
N. gonorrhoeae, 383
S. marcescens, 905
Serratia marcescens
adherence, 906
aminoglycoside resistance, 905
antibiotic resistance, 905
antibiotic susceptibility, 905
antiserum, 251
Concanavalin-A-induced resistance to infection, 251
culture and identification, 904
epidemiological typing, 908, 1027
extracellular products, 904, 907
fluoroquinolone resistance, 458, 906
hydrophobicity, 906
β-lactam resistance, 905
lipopolysaccharide, 907
nosocomial infections, 903, 1027
pathogenicity and virulence, 906
phagocytosis by macrophages, 251
pigmentation, 904
RAPD-PCR typing, 909, 913
resistance to carbapenems, 451
serological typing, 908
Shigella spp.
restriction endonucleases in, 949
Siderophore production, 833
Sinusitis, microbiology of, 430
Sleeping sickness, 10
Smallpox, 8
Soft tissue infection
by *P. lignicola*, 699
Spirochaetes *see Treponema* spp.
Sputum samples, 757
Staphylococci
adherence to prosthetic devices, 75, 285
analysis by multiplex PCR, 773
antibiotic resistance, 28, 439, 448
antibiotic resistance in *S. aureus*, 446
bi-component toxins of *S. aureus*, 479
channel-forming leucotoxins of *S. aureus*, 486
in chronic maxillary sinusitis, 430
coagulase polymorphisms of *S. aureus*, 222
coagulase-negative, 45, 195

discrimination of MRSA, 145
enterotoxin production by *S. aureus*, 214
epidemiological typing, 195
fatty acid modifying enzyme of *S. epidermidis*, 693
food-borne *S. aureus* infection, 214
genome organisation of *S. aureus*, 297
in ITUs, 448
methicillin-resistant *S. aureus*, 145, 214, 297, 439, 446, 448, 773
nasal carriage of *S. aureus*, 222
nosocomial infections, 195, 439
protein A polymorphisms of *S. aureus*, 222
rapid identification by PCR, 45
S. aureus, α-haemolysin, 208
S. aureus arthritis, virulence factors, 208
S. aureus in bacteraemia, 446
S. aureus, fluoroquinolone resistance, 458
S. aureus, protein A, 208, 222
S. aureus, quality control of phage typing, 511
S. aureus, specific chromosomal DNA, 997
surface adhesins in orthopaedic device infections, 75
treatment of *S. aureus* osteomyelitis, 779
vancomycin resistance, 451
vitronectin-mediated adherence, 285
zoonoses, 28
Stenotrophomonas maltophilia
antibiotic resistance and noscomial infections, 436
resistance to carbapenems, 451
Streptococci
S. agalactiae β gene and gene product variations, 1005
S. pneumoniae, fluoroquinolone resistance, 458
S. pneumoniae, antibiotic resistance, 444, 445, 458, 901
S. pneumoniae, in meningitis, 901
S. pneumoniae, penicillin resistance, 444, 445
Streptomyces spp.
self-protection mechanisms, 461
Streptomycin
in treatment of tuberculosis, 531
Surveillance
cultures, in transplant unit, 785
of influenza virus infections, 813
Syphilis, 9, 669
Systemic lupus erythematosus, 413

Tanapox virus, 19
Taxonomy
analysis of staphylococci by multiplex PCR, 773
of *F. necrophorum*, 865
proposed new taxa, 633
Temperature-inducible proteins
of *R. rickettsii*, 839
Tetracycline
resistance of respiratory tract isolates, 443
Tick-borne fever, 4, 267
Toxins
of *B. anthracis*, 267
of *B. pseudomallei*, 557
bi-component, of *S. aureus*, 479
C. difficile toxin A, 953
haemorrhagic toxin of *C. sporogenes*, 270
P. haemolytica leucotoxin, 276
pertussis, in vaccines, 817
putative *M. ulcerans* toxin, 333
S. aureus leucotoxins, 486
vacuolating, of *H. pylori*, 117, 705
see also Cytotoxins, Enterotoxins
Toxoplasma gondii
diagnosis of encephalitis, 597
effects of sample storage on PCR detection, 92
model of recrudescence, 263
tissue cyst-specific antigens, 587
zoonotic infections, 20
Transport media
for oral spirochaetes, 105
recovery of *M. tuberculosis* from biopsy specimens, 260
Treponema spp.
gene probes, 113
monoclonal antibodies, 112
oral, isolation and identification, 104
primary isolation, 106
production of pure culture, 109
recovery and secondary inoculation, 107
sampling methods, 105
storage and maintenance of isolates, 109
structure, 110
T. pallidum, immobilisation test, 669, 965
T. pallidum, influence of cardiolipin antibodies, 965
T. pallidum, lysozyme in immune immobilisation, 669
transport fluid, 105
Trichophyton mentagrophytes
PCR identification of dermatophytes, 1045
var *interdigitale*, 1045
var *mentagrophytes*, 1045
Trichosporon beigelii
GM-CSF-modulated phagocytosis by neutrophils, 321
Trimethoprim
resistance of respiratory tract isolates, 443
Tropheryma whippelii
detection and identification, 340
Trypanosomiasis, 10
Tuberculosis, 9, 495, 531, 847
Tularaemia, 268
Tumour necrosis factor-α
role in experimental listeriosis, 239
Typhoid fever, 1041

Ulcerans disease, 333
Ureaplasma urealyticum
detection in urine, 413
in systemic lupus erythematosus, 413
Urease
gene in *V. parahaemolyticus*, 639
Urinary tract infection
Acinetobacter spp., 723, 738, 740
detection of *U. urealyticum*, 413
pathogenicity of *P. mirabilis*, 407
role of type-1 fimbriae, 403
in sytemic lupus erythematosus, 413

Vaccines
acellular pertussis, 817
B. anthracis, 267
bacterial zoonoses, 267
Borrelia spp., 268
Brucella spp., 267
controlled release, 975
cross-protective immunity, 9
Francisella tularensis, 268
influenza virus, 61, 813
Leptospira spp., 268
M. tuberculosis, 9
malaria, 357
P. falciparum, 357
Q fever, 268
Rickettsia spp., 268
salmonellae as carriers of foreign antigens, 129
transmission-blocking, 358
Y. pestis, 268
Vacuolating toxin
of *H. pylori*, 117, 705
Vancomycin
dependence of enterococci, 450
resistance in enterococci, 150, 442, 448, 449
resistance in staphylococci, 451
Verocytotoxic *E. coli*, 13
Viable but non-culturable bacteria, 629
Vibrios
fingerprinting *V. cholerae* O1 isolates, 941
genetic linkage between *ure* and *trh* in *V. parahaemolyticus*, 639
molecular epidemiology of *V. cholerae* O1, 611
ribotyping *V. cholerae* O1 isolates, 941
V. cholerae antigens, and colonisation, 1011
V. cholerae, detection of toxin genes, 398
V. cholerae, Tn*pho* mutants, 1011
V. mimicus, detection of toxin genes, 398
Viraemia
cytomegalovirus, 717
Viral infections
zoonoses, 4

see also Specific viruses
Virulence factors
Brucella spp., 102
M. catarrhalis, 366
S. aureus, 208, 486
V. parahaemolyticus, 639
Vitronectin
mediation of staphylococcal adhesion, 285

Whipple's disease, 340
Wound infection
Acinetobacter spp., 740

Yaws, 9
Yellow fever, 8
Yersinia pestis
antigens, 268
vaccines, 268

Zinc ions
effect on metallo-β-lactamases, 807
Zoonoses
development of antibiotic resistance, 26
food- and milk-borne infections, 11
hantavirus infections, 13
hydatid disease, 24
Jennerian principle of cross-protective immunity, 6
poxvirus infections, 17
protozoal infections, 20
transmission, 4
vaccines, 267

INDEX OF AUTHORS FOR VOLUME 46

ALELJUNG P A *see* WANG *et al.*, 657
ALI S A *see* TAMIZIFAR *et al.*, 61
AMATUCCI A M *see* LUN *et al.*, 122
AMYES S G B, GEMMELL C G. Antibiotic resistance (review article), 436
ANSORG R *see* RATH *et al.*, 757
ARRAES S M A A, GAZIRI L C J, VIDOTTO M C, SARIDAKIS H O, FELIPE I. Pre-treatment with Concanavalin-A increases resistance of mice to peritoneal infection by *Serratia marcescens*, 251
ASHLEY C, MORHART M, RENNIE R, ZIOLA B. Release of *Candida albicans* yeast antigens upon interaction with human neutrophils *in vitro*, 747

BADR A *see* EL-ZAATARI *et al.*, 372
BAIRD R *see* LIU *et al.*, 1045
BAKER M *see* SMITH AND BAKER, 883
BARER M R. Viable but non-culturable and dormant bacteria: time to resolve an oxymoron and a misnomer?, 629
BARK T *see* KATOULI *et al.*, 571
BARRETT S *see* HAASE *et al.*, 557
BATT R M *see* FLETCHER *et al.*, 67
BAYLE G *see* RABODONIRINA *et al.*, 665
BEVANGER L *see* MAELAND *et al.*, 1005
BHAT D A *see* DESHPANDE *et al.*, 233
BIRLEY H D L, SCHULTZ T F. Kaposi's sarcoma and the new herpesvirus, 433
BLACKWOOD R A, RODE C K, PIERSON C L, BLOCH C A. Pulsed-field gel electrophoresis genomic fingerprinting of hospital *Escherichia coli* bacteraemia isolates, 506
BLOCH C A *see* BLACKWOOD *et al.*, 506
BONDRE V P, SRIVASTAVA R, SINHA V B, SRIVASTAVA B S. Screening of Tn*phoA* mutants of *Vibrio cholerae* O139 for identification of antigens involved in colonisation, 1011
BORKHARDT H-L, ZIELINSKI S. Influence of cardiolipin antibodies on the binding of treponemal specific antibodies in the fluorescence treponemal antibody absorption test and the *Treponema pallidum* immobilisation test, 965
BORKHARDT HERTHA-LORE *see* ZIELINSKI AND BORKHARDT, 669
BORREGO J J *see* RUIZ *et al.*, 623
BORRIELLO S P *see* SMITH *et al.*, 953
BOTTREAU ELISABETH *see* VELGE *et al.*, 681
BRAKSTAD O G *see* MAELAND *et al.*, 1005
BRANDT K *see* CHAN *et al.*, 711
BRAZIER J S *see* HALL *et al.*, 865
BROOK I, FRAZIER E H, FOOTE P A. Microbiology of chronic maxillary sinusitis: comparison between specimens obtained by sinus endoscopy and by surgical drainage, 430
BROWN P D, LEVETT P N. Differentiation of *Leptospira* species and serovars by PCR-restriction endonuclease analysis, arbitrarily primed PCR and low-stringency PCR, 173
BROWN R *see* POXTON *et al.*, 85
BROWN R, LOUGH H G, POXTON I R. Phenotypic characteristics and lipopolysaccharides of human and animal isolates of *Fusobacterium necrophorum*, 873
BROWN S *see* HARNETT *et al.*, 383
BRUEGGEMANN S A *see* CHAMBERLAIN AND BRUEGGEMANN, 693
BURNS S *see* NICOLL *et al.*, 263
BUTT J L *see* VICTOR *et al.*, 847
BUXTON D *see* NICOLL *et al.*, 263

CARLÉN BIRGITTA *see* WANG *et al.*, 657
CASSONE A *see* CASTELLANI PASTORIS *et al.*, 647
CASTAÑEDA E *see* TAMAYO *et al.*, 611
CASTELLANI PASTORIS M, PROIETTI E, MAURI C, CHIANI P, CASSONE A. Suckling CD1 mice as an animal model for studies of *Legionella pneumophila* virulence, 647
CASTRO D *see* RUIZ *et al.*, 623
CAVALLINI MICHELA *see* GARZELLI *et al.*, 933
CHALLACOMBE S J *see* RADFORD *et al.*, 326
CHAMBERLAIN N R, BRUEGGEMANN S A. Characterisation and expression of fatty acid modifying enzyme produced by *Staphylococcus epidermidis*, 693
CHAN E L, BRANDT K, STONEHAM HEATHER, HORSMAN G. Comparison of the Sanofi Diagnostics Pasteur Chlamydia Microplate EIA shortened assay with the original standard assay and cell culture, 711
CHAN S H *see* TAN *et al.*, 164
CHANG D Y, CHEN R J, LEE S C, HUANG S C. Prevalence of single and multiple infection with human papillomaviruses in various grades of cervical neoplasia, 54
CHANG J-J, LEONARD K R, ZHANG Y-X. Structural studies of the surface projections of *Chlamydia trachomatis* by electron microscopy, 1017
CHEN R J *see* CHANG *et al.*, 54
CHHIBBER SANJAY *see* CHOPRA *et al.*, 139
CHIANI P *see* CASTELLANI PASTORIS *et al.*, 647
CHOPRA UPASNA, VOHRA HARPREET, CHHIBBER SANJAY, GANGULY N K, SHARMA SAROJ. TH_1 pattern of cytokine secretion by splenic cells from pyelonephritic mice after in-vitro stimulation with hsp-65 of *Escherichia coli*, 139
CHUNG IRENE *see* RICHARDSON AND CHUNG, 321
CLARK D R *see* LEE *et al.*, 949
COELHO ANA M *see* VICENTE *et al.*, 398
COLLEY JANE *see* CORNEY *et al.*, 927
COLOE S *see* LIU *et al.*, 1045
CONLAN J W. Neutrophils and tumour necrosis factor-α are important for controlling early gastrointestinal stages of experimental murine listeriosis, 239
COOKE D L *see* SMITH *et al.*, 953
COOKSON B *see* GRIBALDO *et al.*, 45
COOTE J G *see* SAADATI *et al.*, 276
CORBEL M J, XING D K L. The current status of acellular pertussis vaccines, 817
CORBEL M J. Recent advances in brucellosis, 101
CORBEL M J. Vaccines against bacterial zoonoses, 267
CORNEY B G, COLLEY JANE, GRAHAM G C. Simplified analysis of pathogenic leptospiral serovars by random amplified polymorphic DNA fingerprinting, 927
COUSINS D V *see* FEIZABADI *et al.*, 501
CRICHTON PAMELA B *see* OLD *et al.*, 617
CURRIE B *see* HAASE *et al.*, 557
CYNAMON M H *see* VICTOR *et al.*, 847
CZIRÓK ÉVA, PRINZ G Y, DÉNES R, REMÉNYI P, HERENDI AGNES. Value of surveillance cultures in a bone marrow transplantation unit, 785

D'ALAGNI MARINA *see* DEL PRETE *et al.*, 495
DANCE D A B *see* TRAKULSOMBOON *et al.*, 565
DANNAOUI E *see* RABODONIRINA *et al.*, 665
DAROUICHE R O, LANDON G C, PATTI J M, NGUYEN L L, FERNAU R C, McDEVITT D, GREENE C, FOSTER T, KLIMA M. Role of *Staphylococcus aureus* surface adhesins in orthopaedic device infections: are results model-dependent?, 75
DATTA USHA *see* SHARMA *et al.*, 1041
DAUGA C, MIRAS I, GRIMONT P A D. Strategy for detection and identification of bacteria based on 16S rRNA genes in suspected cases of Whipple's disease, 340
DEGRAVE W M *see* SANTOS *et al.*, 170
DEICHER H *see* RUNGE *et al.*, 413
DEL PRETE RAFFAELE, MOSCA ADRIANA, D'ALAGNI MARINA, SABATO R, PICCA V, MIRAGLIOTTA G. Detection of *Mycobacterium tuberculosis* DNA in blood of patients with acute pulmonary tuberculosis by polymerase chain reaction and non-isotopic hybridisation assay, 495
DÉNES R *see* CZIRÓK *et al.*, 785
DENOEL P A, VO T K-O, WEYNANTS V E, TIBOR A, GILSON D, ZYGMUNT M S, LIMET J N, LETESSON J-J. Identification of the major T-cell antigens present in the *Brucella melitensis* B115 protein preparation, Brucellergene OCB, 801
DERMOUMI H *see* RATH *et al.*, 757

DESHPANDE R G, KHAN M B, BHAT D A, NAVALKAR R G. Isolation of a contact-dependent haemolysin from *Mycobacterium tuberculosis*, 233
DONALD P R *see* VICTOR *et al.*, 847
DOUGLAS C I *see* READ AND DOUGLAS, 1057
DRGONA L *see* SPANIK *et al.*, 517
DUERDEN B I *see* HALL *et al.*, 865
DUERDEN B I *see* HART *et al.*, 4
DUPPRE NADIA C *see* SANTOS *et al.*, 170

EDWARDS R *see* FEIZABADI *et al.*, 501
EDWARDS R, HASHMI P S, GREENWOOD D. The effect of zinc ions on the activity of metallo-β-lactamases of *Bacteroides fragilis*, 807
EDWARDS R. Resistance to β-lactam antibiotics in *Bacteroides* spp., 985
EHRENSTEIN B *see* SEWARD *et al.*, 314
EL-ADHAMI W, STEWART P R. Genome organisation of *Staphylococcus aureus* isolates from different populations, 297
EL-ADHAMI W A, STEWART P R, MATTHAEI K I. The isolation and cloning of chromosomal DNA specific for a clonal population of *Staphylococcus aureus* by subtractive hybridisation, 997
EL-ZAATARI F A K, WOO J S, BADR A, OSATO M S, SERNA H, LICHTENBERGER L M, GENTA R M, GRAHAM D Y. Failure to isolate *Helicobacter pylori* from stray cats indicates that *H. pylori* in cats may be an anthroponosis – an animal infection with a human pathogen, 372
ELLIS R W. Infection and coronary heart disease, 535
EMBAYE H *see* FLETCHER *et al.*, 67
ENRIGHT M C, McKENZIE H. *Moraxella (Branhamella) catarrhalis* – clinical and molecular aspects of a rediscovered pathogen (review article), 360
ESPERSEN F *see* VAN BELKUM *et al.*, 222

FALCONE G *see* GARZELLI *et al.*, 933
FALKINER F R *see* HEJAZI AND FALKINER, 903
FALKINER F R *see* HEJAZI *et al.*, 913
FAN X G, LI T G. Growth of *Helicobacter pylori* in candle jars, 354
FANTASIA M *see* NASTASI *et al.*, 377
FARINA C, PUNITHALIGHAM E, RUGGENENTI P, GOGLIO A. Phaeohyphomycotic soft tissue disease caused by *Pleurophomopsis lignicola* in a kidney transplant patient, 699
FEIZABADI M M, ROBERTSON I D, EDWARDS R, COUSINS D V, HAMPSON D J. Genetic differentiation of Australian isolates of *Mycobacterium tuberculosis* by pulsed-field gel electrophoresis, 501
FELIPE I *see* ARRAES *et al.*, 251
FELIX J V *see* VICTOR *et al.*, 847
FERGUSON ANNE *see* POXTON *et al.*, 85
FERNAU R C *see* DAROUICHE *et al.*, 75
FIGUEIREDO A M S *see* RESENDE AND FIGUEIREDO, 145
FIGUEIREDO A M S *see* SOARES *et al.*, 214
FILHO J T G *see* SANTOS *et al.*, 170
FINKEN-EIGEN M *see* SCHMITZ *et al.*, 773
FISCHER ELIZABETH R *see* POLICASTRO *et al.*, 839
FLAMENT-SAILLOUR M *see* MATSIOTA-BERNARD *et al.*, 256
FLETCHER J N, SAUNDERS J R, EMBAYE H, ODEDRA R M, BATT R M, HART C A. Surface properties of diarrhoeagenic *Escherichia coli* isolates, 67
FOOTE P A *see* BROOK *et al.*, 430
FORBES K J *see* WELLER *et al.*, 921
FOSTER T *see* DAROUICHE *et al.*, 75
FRAIOLI R *see* LUN *et al.*, 122
FRAZIER E H *see* BROOK *et al.*, 430
FREDERIKSEN W, URSING J. Proposed new bacterial taxa and proposed changes of bacterial names published during 1995 and 1996 and considered to be of interest to medical or veterinary bacteriology, 633
FREEMAN R *see* HANNAN *et al.*, 348
FREEMAN R *see* LEAVES *et al.*, 204
FREITAS F I S *see* SIQUEIRA *et al.*, 486
FRIES E *see* VERKOOYEN *et al.*, 419

GALLO MARIA E N *see* SANTOS *et al.*, 170
GANGULY N K *see* CHOPRA *et al.*, 139
GANGULY N K *see* GUPTA *et al.*, 403
GARZELLI C, LARI NICOLETTA, NGUON B, CAVALLINI MICHELA, PISTELLO M, FALCONE G. Comparison of three restriction endonucleases in IS*1245*-based RFLP typing of *Mycobacterium avium*, 933
GAZIRI L C J *see* ARRAES *et al.*, 251
GEARY C, JORDENS J Z, RICHARDSON J F, HAWCROFT D M, MITCHELL C J. Epidemiological typing of coagulase-negative staphylococci from nosocomial infections, 195
GEMMELL C G *see* AMYES AND GEMMELL, 436
GEMMELL C G, GOUTCHER S C, REID R, STURROCK R D. Role of certain virulence factors in a murine model of *Staphylococcus aureus* arthritis, 208
GENTA R M *see* EL-ZAATARI *et al.*, 372
GIBBS H A *see* SAADATI *et al.*, 276
GIBSON J *see* OWEN *et al.*, 34
GIBSON JANET, LORENZ E, OWEN R J. Lineages within *Campylobacter jejuni* defined by numerical analysis of pulsed-field gel electrophoretic DNA profiles, 157
GILSON D *see* DENOEL *et al.*, 801
GOGLIO A *see* FARINA *et al.*, 699
GOÑI P *see* RUIZ *et al.*, 623
GONZALEZ-HEVIA M ANGELES *see* GUERRA *et al.*, 307
GOULLET P, PICARD B. An epidemiological study of *Serratia marcescens* isolates from nosocomial infections by enzyme electrophoresis, 1027
GOUTCHER S C *see* GEMMELL *et al.*, 208
GRAHAM D Y *see* EL-ZAATARI *et al.*, 372
GRAHAM G C *see* CORNEY *et al.*, 927
GRAY F *see* MATSIOTA-BERNARD *et al.*, 256
GREENE C *see* DAROUICHE *et al.*, 75
GREENMAN J *see* STARK *et al.*, 793
GREENWOOD D *see* EDWARDS *et al.*, 807
GREY E *see* SPANIK *et al.*, 517
GRIBALDO S, COOKSON B, SAUNDERS N, MARPLES R, STANLEY J. Rapid identification by specific PCR of coagulase-negative staphylococcal species important in hospital infection, 45
GRIMONT F *see* TAMAYO *et al.*, 611
GRIMONT P A D *see* DAUGA *et al.*, 340
GRIMONT P A D *see* TAMAYO *et al.*, 611
GRUNDMANN H J *see* SEWARD *et al.*, 314
GUERRA BEATRIZ, LANDERAS ELENA, GONZALEZ-HEVIA M ANGELES, MENDOZA M CARMEN. A three-way ribotyping scheme for *Salmonella* serotype Typhimurium and its usefulness for phylogenetic and epidemiological purposes, 307
GUPTA R, GUPTA S, GANGULY N K. Role of type-1 fimbriae in the pathogenesis of chronic pyelonephritis in relation to reactive oxygen species, 403
GUPTA S *see* GUPTA *et al.*, 403

HAASE A, JANZEN J, BARRETT S, CURRIE B. Toxin production by *Burkholderia pseudomallei* strains and correlation with severity of melioidosis, 557
HACKSTADT T *see* POLICASTRO *et al.*, 839
HALL VAL, DUERDEN B I, MAGEE J T, RYLEY H C, BRAZIER J S. A comparative study of *Fusobacterium necrophorum* strains from human and animal sources by phenotypic reactions, pyrolysis mass spectrometry and SDS-PAGE, 865
HAMPSON D J *see* FEIZABADI *et al.*, 501
HANAWA T *see* YAMAGUCHI *et al.*, 819, 825
HANCOCK R E W. Antibacterial peptides and the outer membranes of gram-negative bacilli, 1
HANNAN P C T, KEARNS A M, SISSON P R, FREEMAN R. Differentiation of strains of *Mycoplasma fermentans* from various sources by pyrolyis mass spectrometry, 348
HARA-KUDO Y, OGURA A, NOGUCHI Y, KUMAGAI S. Characteristics of toxicity and haemorrhagic toxin produced by *Clostridium sporogenes* in various animals and cultured cells, 270
HAREL J *see* VASFI MARANDI *et al.*, 603
HARNETT N, BROWN S, RILEY G, TERRO R, KRISHNAN C, PAUZÉ M, YEUNG K-H. Analysis of *Neissseria gonorrhoeae* in Ontario, Canada, with decreased susceptibility to quinolones by pulsed-field gel electrophoresis, auxotyping, serotyping and plasmid content, 383
HART C A *see* FLETCHER *et al.*, 67
HART C A, TREES A J, DUERDEN B I. Zoonoses (review article), 4
HASHMI P S *see* EDWARDS *et al.*, 807
HASSAN I J *see* STARK *et al.*, 793
HAWCROFT D M *see* GEARY *et al.*, 195

HEINZ H-P *see* SCHMITZ *et al.*, 773
HEJAZI A, FALKINER F R. *Serratia marcescens* (review), 903
HEJAZI A, KEANE C T, FALKINER F R. The use of RAPD-PCR as a typing method for *Serratia marcescens*, 913
HERENDI AGNES *see* CZIRÓK *et al.*, 785
HIRST R G *see* ROBERTS AND HIRST, 333
HO-YEN D O *see* JOSS AND HO-YEN, 92
HOFMANN B *see* SCHMITZ *et al.*, 773
HONDA TAKESHI *see* IIDA *et al.*, 639
HOOSEN A A *see* KHARSANY *et al.*, 579
HORSMAN G *see* CHAN *et al.*, 711
HUANG S C *see* CHANG *et al.*, 54
HYDE S *see* SMITH *et al.*, 953

IDO K *see* WANG *et al.*, 705
IIDA TETSUYA, SUTHIENKUL ORASA, PARK KWON-SAM, TANG GUANG-QING, YAMAMOTO RYOHEI K, ISHIBASHI MASANORI, YAMAMOTO KOICHIRO, HONDA TAKESHI. Evidence for genetic linkage between the *ure* and *trh* genes in *Vibrio parahaemolyticus*, 639
IKEDA F *see* MATSUMOTO *et al.*, 391
ISHIBASHI MASANORI *see* IIDA *et al.*, 639
ITO Y, MORIWAKI H, MUTO Y, KATO N, WATANABE K, UENO K. Effect of lactulose on short-chain fatty acids and lactate production and on the growth of faecal flora, with special reference to *Clostridium difficile*, 80
ITOKAZU M, OHNO T, TANEMORI T, WADA E, KATO N, WATANABE K. Antibiotic-loaded hydroxyapatite blocks in the treatment of experimental osteomyelitis in rats, 779
IUMS Subcommittee *see* MARPLES *et al.*, 511

JANZEN J *see* HAASE *et al.*, 557
JAWAHAR M S *see* VANAJAKUMAR *et al.*, 260
JENNINGS R *see* TAMIZIFAR *et al.*, 61
JORDAAN A M *see* VICTOR *et al.*, 847
JORDENS J Z *see* GEARY *et al.*, 195
JORDENS J Z *see* LEAVES *et al.*, 204
JORDENS J Z, LEAVES N I. Source of variation detected in ribotyping patterns of *Haemophilus influenzae*: comparison of traditional ribotyping, PCR-ribotyping and rDNA restriction analysis, 763
JOSS A W L, HO-YEN D O. The effects of sample storage on polymerase chain reaction-based detection of *Toxoplasma gondii* in amniotic fluids, 92

KAEFFER B *see* VELGE *et al.*, 681
KAM K-M *see* LEE *et al.*, 949
KAMIYA S *see* YAMAGUCHI *et al.*, 819, 825
KAMIYA SHIGERU *see* OSAKI *et al.*, 117
KARITA M *see* MATSUMOTO *et al.*, 391
KATO N *see* ITO *et al.*, 80
KATO N *see* ITOKAZU *et al.*, 779
KATOULI M, NETTEBLADT C G, MURATOV V, LJUNGQVIST O, BARK T, SVENBERG T, MÖLLBY R. Selective translocation of coliform bacteria adhering to caecal epithelium of rats during catabolic stress, 571
KEANE C T *see* HEJAZI *et al.*, 913
KEANE C T *see* LAVERY *et al.*, 150
KEARNS A M *see* HANNAN *et al.*, 348
KHAN M B *see* DESHPANDE *et al.*, 233
KHARSANY A B M, HOOSEN A A, KIEPIELA P, NAICKER T, STURM A W. Growth and cultural characteristics of *Calymmatobacterium granulomatis* – the aetiological agent of granuloma inguinale (Donovanosis), 579
KIEPIELA P *see* KHARSANY *et al.*, 579
KIHIRA K *see* WANG *et al.*, 705
KIMURA K *see* WANG *et al.*, 705
KIRCHHOFF H *see* RUNGE *et al.*, 413
KLIMA M *see* DAROUICHE *et al.*, 75
KLUYTMANS JAN *see* VAN BELKUM *et al.*, 222
KOBLAVI S *see* TAMAYO *et al.*, 611
KÖHRER *see* SCHMITZ *et al.*, 773
KOJIMA T *see* WANG *et al.*, 705
KÖNIG B, PRÉVOST G, KÖNIG W. Composition of staphylococcal bi-component toxins determines pathophysiological reactions, 479
KÖNIG B, VASIL M L, KÖNIG W. Role of haemolytic and non-haemolytic phospholipase C from *Pseudomonas aeruginosa* in interleukin-8 release from human monocytes, 471
KÖNIG W *see* KÖNIG *et al.*, 471, 479
KONISHI H *see* YOKOTA *et al.*, 675
KOREN P *see* SPANIK *et al.*, 517
KRCMERY V *see* SPANIK *et al.*, 517
KRISHNAN C *see* HARNETT *et al.*, 383
KUKUCKOVA E *see* SPANIK *et al.*, 517
KUMADA JUNKO *see* OSAKI *et al.*, 117
KUMAGAI S *see* HARA-KUDO *et al.*, 270
KUNOVA A *see* SPANIK *et al.*, 517
KURIHARA N *see* YAMAGUCHI *et al.*, 825
KVAM A I *see* MAELAND *et al.*, 1005

LACKA J *see* SPANIK *et al.*, 517
LANDERAS ELENA *see* GUERRA *et al.*, 307
LANDON G C *see* DAROUICHE *et al.*, 75
LARI NICOLETTA *see* GARZELLI *et al.*, 933
LAVERY A, ROSSNEY A S, MORRISON D, POWER A, KEANE C T. Incidence and detection of multi-drug-resistant enterococci in Dublin hospitals, 150
LEAVES N I *see* JORDENS AND LEAVES, 763
LEAVES N I, SISSON P R, FREEMAN R, JORDENS J Z. Pyrolysis mass spectrometry in epidemiological and population genetic studies of *Haemophilus influenzae*, 204
LEE EVA *see* WHITTLE *et al.*, 129
LEE K-F, LING JULIA M-L, KAM K-M, CLARK D R, SHAW P-C. Restriction endonucleases in clinical isolates of *Shigella* spp., 949
LEE S C *see* CHANG *et al.*, 54
LEONARD K R *see* CHANG *et al.*, 1017
LETESSON J-J *see* DENOEL *et al.*, 801
LEVETT P N *see* BROWN AND LEVETT, 173
LI T G *see* FAN AND LI, 354
LICHTENBERGER L M *see* EL-ZAATARI *et al.*, 372
LIMET J N *see* DENOEL *et al.*, 801
LIN H-C *see* SHANGKUAN *et al.*, 941
LING JULIA M-L *see* LEE *et al.*, 949
LIU D, COLOE S, BAIRD R, PEDERSEN J. PCR identification of *Trichophyton mentagrophytes* var. *interdigitale* and *T. mentagrophytes* var. *mentagrophytes* dermatophytes with a random primer, 1045
LJUNGH ÅSA *see* LUNDBERG *et al.*, 285
LJUNGQVIST O *see* KATOULI *et al.*, 571
LONG R G *see* SMITH *et al.*, 953
LORENZ E *see* GIBSON *et al.*, 157
LORENZ E *see* OWEN *et al.*, 34
LOUGH H G *see* BROWN *et al.*, 873
LUN M T, RAPONI G, AMATUCCI A M, NATALI P G, FRAIOLI R, MANCINI C. Characterisation and protective capacity of monoclonal antibodies elicited in mice against protein epitopes of antibiotic-exposed *Escherichia coli*, 122
LUNDBERG F, SCHLIAMSER SILVIA, LJUNGH ASÅ. Vitronectin may mediate staphylococcal adhesion to polymer surfaces in perfusing human cerebrospinal fluid, 285

McDEVITT D *see* DAROUICHE *et al.*, 75
MACFARLANE G T *see* MACFARLANE AND MACFARLANE, 547
MACFARLANE S, MACFARLANE G T. Formation of a dipeptidyl arylamidase by *Bacteroides splanchnicus* NCTC 10825 with specificities towards glycylprolyl-x and valylalanine-x substrates, 547
McHUGH T D, BATHGATE T, MANGAN J, JOHNSON J D, HOLLIMAN R E, BUTCHER P D. Recognition of tissue cyst-specific antigens in reactivating toxoplasmosis, 587
MACKENZIE C R *see* SCHMITZ *et al.*, 773
MACKENZIE F M *see* WELLER *et al.*, 921
McKENZIE H *see* ENRIGHT AND McKENZIE, 360
MAELAND J A, BRAKSTAD O G, BEVANGER L, KVAM A I. *Streptococcus agalactiae* β gene and gene product variations, 1005
MAGEE J T *see* HALL *et al.*, 865
MALEY S W *see* NICOLL *et al.*, 263
MAMMINA C *see* NASTASI *et al.*, 377
MANCINI C *see* LUN *et al.*, 122
MARDIAK J *see* SPANIK *et al.*, 517
MARPLES R *see* GRIBALDO *et al.*, 45
MARPLES R R, ROSDAHL V T, Members of IUMS Subcommittee. International quality control of phage typing of *Staphylococcus aureus*, 511

MARTÍNEZ M M *see* RODRÍGUEZ *et al.*, 597
MATSIOTA-BERNARD P, TRUCHIS P DE, GRAY F, FLAMENT-SAILLOUR M, VOYATZAKIS E, NAUCIEL C. JC virus detection in the cerebrospinal fluid of AIDS patients with progressive multifocal leucoencephalopathy and monitoring of the antiviral treatment by a PCR method, 256
MATSUMOTO S, WASHIZUKA Y, MATSUMOTO Y, TAWARA S, IKEDA F, YOKOTA Y, KARITA M. Induction of ulceration and severe gastritis in Mongolian gerbil by *Helicobacter pylori* infection, 391
MATSUMOTO Y *see* MATSUMOTO *et al.*, 391
MATTHAEI K I *see* EL-ADHAMI *et al.*, 997
MATTHAEI K I *see* WHITTLE *et al.*, 1037
MAURI C *see* CASTELLANI PASTORIS *et al.*, 647
MENDOZA M CARMEN *see* GUERRA *et al.*, 307
MILLAR M R *see* STARK *et al.*, 793
MIRAGLIOTTA G *see* DEL PRETE *et al.*, 495
MIRAS I *see* DAUGA *et al.*, 340
MITCHELL C J *see* GEARY *et al.*, 195
MITTAL K R *see* VASFI MARANDI *et al.*, 603
MOJON M *see* RABODONIRINA *et al.*, 665
MÖLLBY R *see* KATOULI *et al.*, 571
MONTEIL H *see* SIQUEIRA *et al.*, 486
MORHART M *see* ASHLEY *et al.*, 747
MORIWAKI H *see* ITO *et al.*, 80
MORRISON D *see* LAVERY *et al.*, 150
MORSHED M G *see* YOKOTA *et al.*, 675
MOSCA ADRIANA *see* DEL PRETE *et al.*, 495
MOUSAVI JOULANDAN S A *see* VERKOOYEN *et al.*, 959
MÜLLER K-D *see* RATH *et al.*, 757
MUNDERLOH ULRIKE G *see* POLICASTRO *et al.*, 839
MURATOV V *see* KATOULI *et al.*, 571
MUTO Y *see* ITO *et al.*, 80

NAICKER T *see* KHARSANY *et al.*, 579
NAIDU A J, YADAV M. Influence of iron, growth temperature and plasmids on siderophore production in *Aeromonas hydrophila*, 833
NAKAZAWA T *see* YOKOTA *et al.*, 675
NASTASI A, MAMMINA C, FANTASIA M, PONTELLO M. Epidemiological analysis of strains of *Salmonella enterica* serotype Enteritidis from foodborne outbreaks occurring in Italy, 1980–1994, 377
NATALI P G *see* LUN *et al.*, 122
NAUCIEL C *see* MATSIOTA-BERNARD *et al.*, 256
NAVALKAR R G *see* DESHPANDE *et al.*, 233
NERY J C *see* SANTOS *et al.*, 170
NETTEBLADT C G *see* KATOULI *et al.*, 571
NG W C *see* TAN *et al.*, 164
NGUON B *see* GARZELLI *et al.*, 933
NGUYEN L L *see* DAROUICHE *et al.*, 75
NICOLL S, WRIGHT S, MALEY S W, BURNS S, BUXTON D. A mouse model of recrudescence of *Toxoplasma gondii* infection, 263
NILSSON H-O *see* WANG *et al.*, 657
NOGUCHI Y *see* HARA-KUDO *et al.*, 270
NOLETO A L S *see* SOARES *et al.*, 214

ODEDRA R M *see* FLETCHER *et al.*, 67
OGATA SACHIO *see* OSAKI *et al.*, 117
OGURA A *see* HARA-KUDO *et al.*, 270
OHMORI C *see* WANG *et al.*, 705
OHNO T *see* ITOKAZU *et al.*, 779
OLD D C, CRICHTON PAMELA B, TAYLOR A, RANKIN S C. Phenotypic and genotypic discrimination of strains of *Salmonella* serotype Eimsbuettel from human and animal sources, 617
ORAVCOVA E *see* SPANIK *et al.*, 517
OSAKI T *see* YAMAGUCHI *et al.*, 819, 825
OSAKI TAKAKO, YAMAGUCHI HIROYUKI, TAGUCHI HARUHIKO, KUMADA JUNKO, OGATA SACHIO, KAMIYA SHIGERU. Studies on the relationship between adhesive activity and haemagglutination by *Helicobacter pylori*, 117
OSATO M S *see* EL-ZAATARI *et al.*, 372
OWEN R J *see* GIBSON *et al.*, 157
OWEN R J, LORENZ E, GIBSON J. Application of the Mast resistotyping scheme to *Campylobacter jejuni* and *C. coli*, 34

PARAMASIVAN C N *see* VANAJAKUMAR *et al.*, 260
PARIJA S C *see* RAVINDER *et al.*, 859
PARK KWON-SAM *see* IIDA *et al.*, 639
PARTON R *see* SAADATI *et al.*, 276
PATTI J M *see* DAROUICHE *et al.*, 75
PAUZÉ M *see* HARNETT *et al.*, 383
PEDERSEN J *see* LIU *et al.*, 1045
PELTOLA H. Controversies in the management of childhood meningitis, 901
PERSAT F *see* RABODONIRINA *et al.*, 665
PICARD B *see* GOULLET AND PICARD, 1027
PICCA V *see* DEL PRETE *et al.*, 495
PICHNA P *see* SPANIK *et al.*, 517
PIERSON C L *see* BLACKWOOD *et al.*, 506
PINNEY R J *see* THROWER *et al.*, 425
PISTELLO M *see* GARZELLI *et al.*, 933
PITT T L *see* TRAKULSOMBOON *et al.*, 565
POLICASTRO P F, MUNDERLOH ULRIKE G, FISCHER ELIZABETH R, HACKSTADT T. *Rickettsia rickettsii* growth and temperature-inducible protein expression in embryonic tick cell lines, 839
PONTELLO M *see* NASTASI *et al.*, 377
POTTER C W *see* TAMIZIFAR *et al.*, 61
POWER A *see* LAVERY *et al.*, 150
POXTON I R *see* BROWN *et al.*, 873
POXTON I R, BROWN R, SAWYERR A, FERGUSON ANNE. Mucosa-associated bacterial flora of the human colon, 85
PRÉVOST G *see* KÖNIG *et al.*, 479
PRÉVOST G *see* SIQUEIRA *et al.*, 486
PRINZ G Y *see* CZIRÓK *et al.*, 785
PROIETTI E *see* CASTELLANI PASTORIS *et al.*, 647
PUNITHALIGHAM E *see* FARINA *et al.*, 699

RABODONIRINA M, WILMOTTE R, DANNAOUI E, PERSAT F, BAYLE G, MOJON M. Detection of *Pneumocystis carinii* DNA by PCR amplification in various rat organs in experimental pneumocystosis, 665
RADFORD D R, CHALLACOMBE S J, WALTER J D. Scanning electron microscopy of the development of structured aerial mycelia and satellite colonies of phenotypically switched *Candida albicans*, 326
RAJARAM K *see* VANAJAKUMAR *et al.*, 260
RANKIN S C *see* OLD *et al.*, 617
RAPONI G *see* LUN *et al.*, 122
RATH P-M, MÜLLER K-D, DERMOUMI H, ANSORG R. A comparison of methods of phenotypic and genotypic fingerprinting of *Exophiala dermatitidis* isolated from sputum samples of patients with cystic fibrosis, 757
RAVINDER P T, PARIJA S C, SUBBA RAO K S V K. Evaluation of human hydatid disease before and after surgery and chemotherapy by demonstration of hydatid antigens and antibodies in serum, 859
READ R C, DOUGLAS C I. Proceedings of the 175th meeting of the Pathological Society of Great Britain and Ireland, 1057
REID R *see* GEMMELL *et al.*, 208
REMÉNYI P *see* CZIRÓK *et al.*, 785
RENNIE R *see* ASHLEY *et al.*, 747
RESENDE C A, FIGUEIREDO A M S. Discrimination of methicillin-resistant *Staphylococcus aureus* from borderline-resistant and susceptible isolates by different methods, 145
RICHARDSON J F *see* GEARY *et al.*, 195
RICHARDSON M *see* VICTOR *et al.*, 847
RICHARDSON M D, CHUNG IRENE. GM-CSF-modulated phagocytosis of *Trichosporon beigelii* by human neutrophils, 321
RICHARDSON M D. Lipid complexes of amphotericin B: the competitive picture, 185
RIEWARTS ERIKSEN N H *see* VAN BELKUM *et al.*, 222
RILEY G *see* HARNETT *et al.*, 383
ROBERTS BRENDA, HIRST R G. Diagnostic potential of a serological assay for the diagnosis of ulcerans disease based on the putative *Mycobacterium ulcerans* toxin, 333
ROBERTSON I D *see* FEIZABADI *et al.*, 501
RODE C K *see* BLACKWOOD *et al.*, 506
RODRÍGUEZ J C, MARTÍNEZ M M, ROYO G. Evaluation of different techniques in the diagnosis of *Toxoplasma* encephalitis, 597
ROSDAHL V T *see* MARPLES *et al.*, 511
ROSSNEY A S *see* LAVERY *et al.*, 150
ROYO G *see* RODRÍGUEZ *et al.*, 597
RUGGENENTI P *see* FARINA *et al.*, 699

RUIZ J, CASTRO D, GOÑI P, SANTAMARIA J A, BORREGO J J, VILA J. Analysis of the mechanism of quinolone resistance in nalidixic acid-resistant clinical isolates of *Salmonella* serotype Typhimurium, 623
RUNGE M, RYKENA S, WILDHAGEN K, DEICHER H, KIRCHHOFF H. Detection of *Ureaplasma urealyticum* in urine of patients with systemic lupus erythematosus and healthy individuals by culture and polymerase chain reaction, 413
RUPAR R *see* WANG *et al.*, 657
RYKENA S *see* RUNGE *et al.*, 413
RYLEY H C *see* HALL *et al.*, 865

SAADATI M, GIBBS H A, PARTON R, COOTE J G. Characterisation of the leukotoxin produced by different strains of *Pasteurella haemolytica*, 276
SABATO R *see* DEL PRETE *et al.*, 495
SAHEL J *see* SIQUEIRA *et al.*, 486
SAIFUKU K *see* WANG *et al.*, 705
SALEK T *see* SPANIK *et al.*, 517
SALLES C A *see* VICENTE *et al.*, 398
SANTAMARIA J A *see* RUIZ *et al.*, 623
SANTOS A R, NERY J C, DUPPRE NADIA C, GALLO MARIA E N, FILHO J T G, SUFFYS P N, DEGRAVE W M. Use of the polymerase chain reaction in the diagnosis of leprosy, 170
SARIDAKIS H O *see* ARRAES *et al.*, 251
SASIAK A B, SESARDIC D. Controlled release vaccines, 975
SATOH K *see* WANG *et al.*, 705
SAUNDERS J R *see* FLETCHER *et al.*, 67
SAUNDERS N *see* GRIBALDO *et al.*, 45
SAWYERR A *see* POXTON *et al.*, 85
SCHAAF H S *see* VICTOR *et al.*, 847
SCHLIAMSER SILVIA *see* LUNDBERG *et al.*, 285
SCHMITZ F-J, MACKENZIE C R, HOFMANN B, VERHOEF J, FINKEN-EIGEN H-P, KÖHRER K. Specific information concerning taxonomy, pathogenicity and methicillin resistance of staphylococci obtained by a multiplex PCR, 773
SCHULTZ T F *see* BIRLEY AND SCHULTZ, 433
SEHGAL SHOBHA *see* SHARMA *et al.*, 1041
SEKI M *see* WANG *et al.*, 705
SELVAKUMAR N *see* VANAJAKUMAR *et al.*, 260
SENIOR B W. Media for the detection and recognition of the enteropathogen *Providencia alcalifaciens* in faeces, 524
SENIOR B W. Media and tests to simplify the recognition and identification of members of the *Proteeae*, 39
SENIOR B W. The ability of a *Proteus mirabilis* strain to invade the bloodstream is independent of its proticine production/proticine sensitivity type, 407
SERNA H *see* EL-ZAATARI *et al.*, 372
SESARDIC D *see* SASIAK AND SESARDIC, 975
SEWARD R J, EHRENSTEIN B, GRUNDMANN H J, TOWNER K J. Direct comparison of two commercially available computer programs for analysing DNA fingerprinting gels, 314
SHANGKUAN Y-H, TSAO C-M, LIN H-C. Comparison of *Vibrio cholerae* O1 isolates by polymerase chain reaction fingerprinting and ribotyping, 941
SHARMA MEERA, DATTA USHA, VERMA S, SEHGAL SHOBHA. Low sensitivity of counter-current immuno-electrophoresis for serodiagnosis of typhoid fever, 1041
SHARMA SAROJ *see* CHOPRA *et al.*, 139
SHAW P-C *see* LEE *et al.*, 949
SHORTRIDGE K F. The influenza conundrum, 813
SIJMONS M *see* VERKOOYEN *et al.*, 419
SIJMONS MARLY *see* VAN BELKUM *et al.*, 222
SINHA V B *see* BONDRE *et al.*, 1011
SIQUEIRA J A, SPEEG-SCHATZ C, FREITAS F I S, SAHEL J, MONTEIL H, PRÉVOST G. Channel-forming leucotoxins from *Staphylococcus aureus* cause severe inflammatory reactions in a rabbit eye model, 486
SIRGEL F A *see* VICTOR *et al.*, 847
SISSON P R *see* HANNAN *et al.*, 348
SISSON P R *see* LEAVES *et al.*, 204
SMITH A, BAKER M. Cefsulodin chocolate blood agar: a selective medium for the recovery of *Haemophilus influenzae* from the respiratory secretions of patients with cystic fibrosis, 883
SMITH G R, THORNTON E A. Classification of human and animal strains of *Fusobacterium necrophorum* by their pathogenic effects in mice, 879
SMITH J A, COOKE D L, HYDE S, BORRIELLO S P, LONG R G. *Clostridium difficile* toxin A binding to human intestinal epithelial cells, 953
SMITH M D *see* TRAKULSOMBOON *et al.*, 565
SMITH ROBYN M *see* WHITTLE *et al.*, 1037
SNIJDER R J *see* VERKOOYEN *et al.*, 959
SOARES M J S, TOKUMARU-MIYAZAKI N H, NOLETO A L S, FIGUEIREDO A M S. Enterotoxin production by *Staphylococcus aureus* clones and detection of Brazilian MRSA clone (III::B:A) among isolates from food handlers, 214
SPANIK S, TRUPL J, KUNOVA A, DRGONA L, SALEK T, MARDIAK J, KUKUCKOVA E, STUDENA M, PICHNA P, ORAVCOVA E, GREY E, KOREN P, SVEC J, LACKA J, SUFLIARSKY J, KRCMERY V. Risk factors, aetiology, therapy and outcome in 123 episodes of breakthrough bacteraemia and fungaemia during antimicrobial prophylaxis and therapy in cancer patients, 517
SPEEG-SCHATZ C *see* SIQUEIRA *et al.*, 486
SRIVASTAVA B S *see* BONDRE *et al.*, 1011
SRIVASTAVA R *see* BONDRE *et al.*, 1011
STANLEY J *see* GRIBALDO *et al.*, 45
STARK R M, SULEIMAN M-S, HASSAN I J, GREENMAN J, MILLAR M R. Amino acid utilisation and deamination of glutamine and asparagine by *Helicobacter pylori*, 793
STEWART P R *see* EL-ADHAMI AND STEWART, 297
STEWART P R *see* EL-ADHAMI *et al.*, 997
STONEHAM HEATHER *see* CHAN *et al.*, 711
STUDENA M *see* SPANIK *et al.*, 517
STUREGÅRD E *see* WANG *et al.*, 657
STURM A W *see* KHARSANY *et al.*, 579
STURROCK R D *see* GEMMELL *et al.*, 208
SUBBA RAO K S V K *see* RAVINDER *et al.*, 859
SUFFYS P N *see* SANTOS *et al.*, 170
SUFLIARSKY J *see* SPANIK *et al.*, 517
SULEIMAN M-S *see* STARK *et al.*, 793
SUTHIENKUL ORASA *see* IIDA *et al.*, 639
SVEC J *see* SPANIK *et al.*, 517
SVENBERG T *see* KATOULI *et al.*, 571

TAGUCHI H *see* YAMAGUCHI *et al.*, 819, 825
TAGUCHI HARUHIKO *see* OSAKI *et al.*, 117
TAKAOKA T *see* WANG *et al.*, 705
TAMAYO M, KOBLAVI S, GRIMONT F, CASTAÑEDA E, GRIMONT P A D. Molecular epidemiology of *Vibrio cholerae* O1 isolates from Colombia, 611
TAMIZIFAR H, JENNINGS R, ALI S A, POTTER C W. Induction of IL-2 and IFN-γ in BALB/c mice immunised with subunit influenza A vaccine in combination with whole cell or acellular DTP vaccine, 61
TAN MENG F, NG W C, CHAN S H, TAN WAN C. Comparative usefulness of PCR in the detection of *Mycobacterium tuberculosis* in different clinical specimens, 164
TAN WAN C *see* TAN *et al.*, 164
TANEMORI T *see* ITOKAZU *et al.*, 779
TANG GUANG-QING *see* IIDA *et al.*, 639
TANIGUCHI Y *see* WANG *et al.*, 705
TARGETT G A T. The search for an effective malaria vaccine, 357
TAWARA S *see* MATSUMOTO *et al.*, 391
TAYLER ELIZABETH. Antituberculosis drug resistance: practical solutions to practical problems, 531
TAYLOR A *see* OLD *et al.*, 617
TERRO R *see* HARNETT *et al.*, 383
THORNTON E A *see* SMITH AND THORNTON, 879
THROWER YVONNE, PINNEY R J, WILSON M. Susceptibilities of *Actinobacillus actinomycetemcomitans* biofilms to oral antiseptics, 425
TIBOR A *see* DENOEL *et al.*, 801
TOKUMARU K *see* WANG *et al.*, 705
TOKUMARU-MIYAZAKI N H *see* SOARES *et al.*, 214
TONG C Y W. Diagnosis of cytomegalovirus infection and disease, 717
TOWNER K J *see* SEWARD *et al.*, 314
TOWNER K J. Clinical importance and antibiotic resistance of *Acinetobacter* spp., 721
TRAKULSOMBOON S, DANCE D A B, SMITH M D, WHITE N J, PITT T L. Ribotype differences between clinical and environmental isolates of *Burkholderia pseudomallei*, 565
TREES A J *see* HART *et al.*, 4
TRUCHIS P DE *see* MATSIOTA-BERNARD *et al.*, 256

TRUPL J *see* SPANIK *et al.*, 517
TSAO C-M *see* SHANGKUAN *et al.*, 941

UCHIDA J Y *see* WANG *et al.*, 705
UENO K *see* ITO *et al.*, 80
URSING J *see* FREDERIKSEN AND URSING, 633
UTT M, WADSTRÖM T. Identification of heparan sulphate binding surface proteins of *Helicobacter pylori*: inhibition of heparan sulphate binding with sulphated carbohydrate polymers, 541

VAN BELKUM A *see* VERKOOYEN *et al.*, 419
VAN BELKUM A, RIEWARTS ERIKSEN N H, SIJMONS MARLY, VAN LEEUWEN W, VAN DEN BERGH MARJOLEIN, KLUYTMANS JAN, ESPERSEN F, VERBRUGH H. Coagulase and protein A polymorphisms do not contribute to persistence of nasal colonisation by *Staphylococcus aureus*, 222
VAN DEN BERGH MARJOLEIN *see* VAN BELKUM *et al.*, 222
VAN DEN BOSCH J M *see* VERKOOYEN *et al.*, 959
VAN ELDERE J *see* VANEECHOUTTE AND VAN ELDERE, 188
VAN HELDEN H P *see* VERKOOYEN *et al.*, 959
VAN HELDEN P D *see* VICTOR *et al.*, 847
VAN LEEUWEN W *see* VAN BELKUM *et al.*, 222
VAN LENT N A *see* VERKOOYEN *et al.*, 959
VAN-LANGENDONCK NATHALIE *see* VELGE *et al.*, 681
VANAJAKUMAR, SELVAKUMAR N, JAWAHAR M S, RAJARAM K, PARAMASIVAN C N. Transportation of lymph node biopsy specimens in selective Kirchner's liquid medium for culture of tubercle bacilli, 260
VANEECHOUTTE M, VAN ELDERE J. The possibilities and limitations of nucleic acid amplification technology in diagnostic microbiology, 188
VASFI MARANDI M, HAREL J, MITTAL K R. Identification by monoclonal antibodies of serotype D strains of *Pasteurella multocida* representing various geographic origins and host species, 603
VASIL M L *see* KÖNIG *et al.*, 471
VELGE P, BOTTREAU ELISABETH, VAN-LANGENDONCK NATHALIE, KAEFFER B. Cell proliferation enhances entry of *Listeria monocytogenes* into intestinal epithelial cells by two proliferation-dependent entry pathways, 681
VENTER A *see* VICTOR *et al.*, 847
VERBRUGH H *see* VAN BELKUM *et al.*, 222
VERBRUGH H A *see* VERKOOYEN *et al.*, 419, 959
VERHOEF J *see* SCHMITZ *et al.*, 773
VERKOOYEN R P, SIJMONS M, FRIES E, VAN BELKUM A, VERBRUGH H A. Widely used, commercially available *Chlamydia pneumoniae* antigen contaminated with mycoplasma, 419
VERKOOYEN R P, VAN LENT N A, MOUSAVI JOULANDAN S A, SNIJDER R J, VAN DEN BOSCH J M, VAN HELDEN H P, VERBRUGH H A. Diagnosis of *Chlamydia pneumoniae* infection in patients with chronic obstructive pulmonary disease by micro-immunofluorescence and ELISA, 959
VERMA NARESH K *see see* WHITTLE *et al.*, 129, 1037
VERMA S *see* SHARMA *et al.*, 1041
VICENTE ANA C P, COELHO ANA M, SALLES C A. Detection of *Vibrio cholerae* and *V. mimicus* heat-stable toxin gene sequence by PCR, 398
VICTOR T C, WARREN R, BUTT J L, JORDAAN A M, FELIX J V, VENTER A, SIRGEL F A, SCHAAF H S, DONALD P R, RICHARDSON M, CYNAMON M H, VAN HELDEN P D. Genome and MIC stability in *Mycobacterium tuberculosis* and indications for continuation of use of isoniazid in multidrug-resistant tuberculosis, 847
VIDOTTO M C *see* ARRAES *et al.*, 251
VILA J *see* RUIZ *et al.*, 623
VO T K-O *see* DENOEL *et al.*, 801
VOHRA HARPREET *see* CHOPRA *et al.*, 139
VOYATZAKIS E *see* MATSIOTA-BERNARD *et al.*, 256

WADA E *see* ITOKAZU *et al.*, 779
WADSTRÖM T *see* UTT AND WADSTRÖM, 541
WADSTRÖM T *see* WANG *et al.*, 657
WALTER J D *see* RADFORD *et al.*, 326
WANG X, STUREGARD E, RUPAR R, NILSSON H-O, ALELJUNG P A, CARLÉN BIRGITTA, WILLÉN R, WADSTRÖM T. Infection of BALB/c A mice by spiral and coccoid forms of *Helicobacter pylori*, 657
WANG X M, KOJIMA T, SATOH K, TANIGUCHI Y, TOKUMARU K, SAIFUKU K, SEKI M, KIHIRA K, IDO K, UCHIDA J Y, OHMORI C, TAKAOKA T, KIMURA K. The value of LYM-1 cells for examining vacuole formation and loss of cell viability induced by culture supernates of *Helicobacter pylori*, 705
WARDLE HELEN M. The challenge of growing oral spirochaetes, 104
WARREN R *see* VICTOR *et al.*, 847
WASHIZUKA Y *see* MATSUMOTO *et al.*, 391
WATANABE K, 80, 779
WATANABE K *see* ITO *et al.*; ITOKAZU *et al.*
WEIR R C *see* WHITTLE *et al.*, 129
WELLER T M A, MacKENZIE F M, FORBES K J. Molecular epidemiology of a large outbreak of multiresistant *Klebsiella pneumoniae*, 921
WEYNANTS V E *see* DENOEL *et al.*, 801
WHITE N J *see* TRAKULSOMBOON *et al.*, 565
WHITTLE BELINDA L, LEE EVA, WEIR R C, VERMA NARESH K. Immune response to a Murray Valley encephalitis virus epitope expressed in the flagellin of an attenuated strain of *Salmonella*, 129
WHITTLE BELINDA L, SMITH ROBYN M, MATTHAEI K I, YOUNG I G, VERMA NARESH K. Enhancement of the specific mucosal IgA response *in vivo* by interleukin-5 expressed by an attenuated strain of *Salmonella* serotype Dublin, 1037
WILDHAGEN K *see* RUNGE *et al.*, 413
WILLÉN R *see* WANG *et al.*, 657
WILMOTTE R *see* RABODONIRINA *et al.*, 665
WILSON M *see* THROWER *et al.*, 425
WOO J S *see* EL-ZAATARI *et al.*, 372
WRIGHT S *see* NICOLL *et al.*, 263

XING D K L *see* CORBEL AND XING, 817

YADAV M *see* NAIDU AND YADAV, 833
YAMAGUCHI H, OSAKI T, KURIHARA N, TAGUCHI H, HANAWA T, YAMAMOTO T, KAMIYA S. Heat-shock protein 60 homologue of *Helicobacter pylori* is associated with adhesion of *H. pylori* to human gastric epithelial cells, 825
YAMAGUCHI H, OSAKI T, TAGUCHI H, HANAWA T, YAMAMOTO T, KAMIYA S. Production and characterisation of monoclonal antibodies to heat-shock protein 60 of *Helicobacter pylori*, 819
YAMAGUCHI HIROYUKI *see* OSAKI *et al.*, 117
YAMAMOTO KOICHIRO *see* IIDA *et al.*, 639
YAMAMOTO RYOHEI K *see* IIDA *et al.*, 639
YAMAMOTO T *see* YAMAGUCHI *et al.*, 819, 825
YEUNG K-H *see* HARNETT *et al.*, 383
YOKOTA M, MORSHED M G, NAKAZAWA T, KONISHI H. Protective activity of *Borrelia duttonii*-specific immunoglobulin subclasses in mice, 675
YOKOTA Y *see* MATSUMOTO *et al.*, 391
YOUNG I G *see* WHITTLE *et al.*, 1037

ZHANG Y-X *see* CHANG *et al.*, 1017
ZIELINSKI S *see* BORKHARDT AND ZIELINSKI, 965
ZIELINSKI SUSANNE, BORKHARDT HERTHA-LORE. Studies on the lysozyme independence of immune immobilisation of *Treponema pallidum* and the frequency of lysozyme autoantibodies in syphilitic sera, 669
ZIOLA B *see* ASHLEY *et al.*, 747
ZYGMUNT M S *see* DENOEL *et al.*, 801